Bispecific antibody News and Research

RSS
Cancer drug offers life-changing results for severe lupus patient

Cancer drug offers life-changing results for severe lupus patient

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Wistar scientists develop Persistent Multivalent T Cell Engager for advanced kidney cancer

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

New method enhances the efficacy of bispecific antibody therapies in treating solid tumors

New method enhances the efficacy of bispecific antibody therapies in treating solid tumors

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants

Novel bispecific antibodies show promise against evolving SARS-CoV-2 variants

Research unveils bispecific antibodies for B-cell lymphoma treatment

Research unveils bispecific antibodies for B-cell lymphoma treatment

Therapeutic potential of CD20 x CD3 bispecific antibodies

Therapeutic potential of CD20 x CD3 bispecific antibodies

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

B-BiTE modality enhances anti-myeloma effects of clinically available antibodies

B-BiTE modality enhances anti-myeloma effects of clinically available antibodies

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

MHRA grants conditional marketing authorization for AbbVie's Tepkinly to treat aggressive blood cancer

New kidney tissue model could help assess safety of immunotherapy drugs

New kidney tissue model could help assess safety of immunotherapy drugs

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

Checkpoint inhibitors may not be effective lymphoma treatment when CAR T fails

Bispecific antibody shows improved efficacy against SARS-CoV-2  variants

Bispecific antibody shows improved efficacy against SARS-CoV-2 variants

Researchers develop innovative STAb therapy for a type of leukemia

Researchers develop innovative STAb therapy for a type of leukemia

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Targeted therapies and novel drug combinations show promise for the treatment of multiple leukemias

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Off-the-shelf immunotherapy could offer new hope for patients with hard-to-treat multiple myeloma

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.